Expertise in
12
conditions

Dr. Dareen D. Siri

Allergy and Immunology
Sneeze Wheeze & Itch Assoc L L C
2151 W White Oaks Dr, 
Springfield,, IL 
Accepting New Patients
Expertise in
12
conditions
Sneeze Wheeze & Itch Assoc L L C
2151 W White Oaks Dr, 
Springfield,, IL 

Overview

Dareen Siri is an Allergy and Immunologist practicing medicine in Springfield,, Illinois.

Dr. Siri is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Sinusitis, and Allergic Rhinitis.

She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 10 clinical trials. Dr. Siri is currently accepting new patients.

Specialties

Allergy and Immunology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Sneeze Wheeze & Itch Assoc L L C
2151 W White Oaks Dr, Springfield,, IL 62704
Other Locations
Ambulatory Medical Associates LLC
2010 Jacobssen Dr, Normal, IL 61761

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein
Enrollment Status: Completed
Publish Date: June 08, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

9 Total Publications

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
Journal: American journal of clinical dermatology
Published: December 23, 2025
Similar Doctors
Expertise in
7
conditions
Dr. Bethany T. Gibson
Allergy and Immunology
Expertise in
7
conditions
Dr. Bethany T. Gibson
Allergy and Immunology
Referral may be required

Office

101 W McKinley Ave, 
Decatur, IL 
 (40.5 miles away)
217-876-3682
Languages Spoken:
English
See accepted insurances

Bethany Gibson is an Allergy and Immunologist practicing medicine in Decatur, Illinois. Dr. Gibson is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sinusitis, Nonallergic Rhinopathy, Allergic Rhinitis, and Grass Allergy.

Expertise in
5
conditions
Dr. Renu C. Govindaiah
Allergy and Immunology
Expertise in
5
conditions
Dr. Renu C. Govindaiah
Allergy and Immunology
Referral may be required

Springfield Clinic LLP

1025 S 6th St, 
Springfield, IL 
 (3.5 miles away)
217-528-7541
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Renu Govindaiah is an Allergy and Immunologist practicing medicine in Springfield, Illinois. Dr. Govindaiah is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Allergic Rhinitis, Sinusitis, Hives, and Grass Allergy. Dr. Govindaiah is currently accepting new patients.

Expertise in
4
conditions
Dr. Sudha G. Prasad
Allergy and Immunology
Expertise in
4
conditions
Dr. Sudha G. Prasad
Allergy and Immunology
Referral may be required

Sudha Prasad M.D.S.C.

901 S Koke Mill Rd, 
Springfield, IL 
 (0.9 miles away)
217-546-4868
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sudha Prasad is an Allergy and Immunologist practicing medicine in Springfield, Illinois. Dr. Prasad is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Allergic Rhinitis, Sinusitis, Grass Allergy, and Chinese Restaurant Syndrome. Dr. Prasad is currently accepting new patients.

Frequently Asked Questions about Dr. Dareen D. Siri

How do I make an appointment with Dr. Dareen D. Siri?

You can book an appointment with Dr. Dareen D. Siri by calling their office at 217-717-4404. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dareen D. Siri a top-rated expert for Primary Immunodeficiency (PID)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dareen D. Siri is classified as an Distinguished expert for Primary Immunodeficiency (PID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dareen D. Siri specialize in?

While Dr. Dareen D. Siri is a Allergy and Immunology, they have specific expertise in Primary Immunodeficiency (PID), Common Variable Immune Deficiency, and Sinusitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Dareen D. Siri participate in research or clinical trials?

Yes. Dr. Dareen D. Siri has published 9 articles and abstracts on conditions like Primary Immunodeficiency (PID). You can view a list of Dr. Dareen D. Siri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dareen D. Siri accept my insurance?

Dr. Dareen D. Siri accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 217-717-4404 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siri's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile